Jade Biosciences (JBIO) Cash & Equivalents (2020 - 2026)

Jade Biosciences (JBIO) has 7 years of Cash & Equivalents data on file, last reported at $55.1 million in Q1 2026.

• Quarterly Cash & Equivalents rose 24.57% year-over-year to $55.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $55.1 million (up 24.57% YoY) and the FY2025 annual result came in at $88.4 million, up 27.46% from the prior year.
• Cash & Equivalents eased to $55.1 million in Q1 2026, from $88.4 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $220.9 million in Q2 2025 to a low of $9.1 million in Q1 2024.
• A 5-year average of $54.8 million and a median of $31.1 million in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents tumbled 87.61% — and 2025, when it jumped 611.0%.
• Tracing JBIO's Cash & Equivalents over 5 years: stood at $22.4 million in 2022, then rose by 4.88% to $23.5 million in 2023, then soared by 195.37% to $69.4 million in 2024, then grew by 27.46% to $88.4 million in 2025, then slumped by 37.71% to $55.1 million in 2026.
• The last three Cash & Equivalents figures came in at $55.1 million (Q1 2026), $88.4 million (Q4 2025), and $50.1 million (Q3 2025), per Business Quant data.